Association of COVID-19 with Comorbidities: An Update

J 2023

Association of COVID-19 with Comorbidities: An Update

CHATTERJEE, Sayan, Lakshmi Vineela NALLA, Monika SHARMA, Nishant SHARMA, Aditya A SINGH et. al.

Základní údaje

Originální název

Association of COVID-19 with Comorbidities: An Update

Autoři

Vydání

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, WASHINGTON, AMER CHEMICAL SOC, 2023, 2575-9108

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.000 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133384

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1021/acsptsci.2c00181

UT WoS

000939529100001

Klíčová slova anglicky

COVID-19; comorbidity; diabetes; cancer; Parkinson?s disease; cardiovascular disease

Štítky

14110515, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 2. 2024 13:56, Mgr. Tereza Miškechová

Anotace

V originále

Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and jeopardized human lives. It spreads at an unprecedented rate worldwide, with serious and still-unfolding health conditions and economic ramifications. Based on the clinical investigations, the severity of COVID-19 appears to be highly variable, ranging from mild to severe infections including the death of an infected individual. To add to this, patients with comorbid conditions such as age or concomitant illnesses are significant predictors of the disease's severity and progression. SARS-CoV-2 enters inside the host cells through ACE2 (angiotensin converting enzyme2) receptor expression; therefore, comorbidities associated with higher ACE2 expression may enhance the virus entry and the severity of COVID-19 infection. It has already been recognized that age-related comorbidities such as Parkinson's disease, cancer, diabetes, and cardiovascular diseases may lead to life-threatening illnesses in COVID-19-infected patients. COVID-19 infection results in the excessive release of cytokines, called "cytokine storm", which causes the worsening of comorbid disease conditions. Different mechanisms of COVID-19 infections leading to intensive care unit (ICU) admissions or deaths have been hypothesized. This review provides insights into the relationship between various comorbidities and COVID-19 infection. We further discuss the potential pathophysiological correlation between COVID-19 disease and comorbidities with the medical interventions for comorbid patients. Toward the end, different therapeutic options have been discussed for COVID-19-infected comorbid patients.

Citovat

CHATTERJEE, Sayan, Lakshmi Vineela NALLA, Monika SHARMA, Nishant SHARMA, Aditya A SINGH, Fehmina Mushtaque MALIM, Manasi GHATAGE, Mohd MUKARRAM, Abhijeet PAWAR, Nidhi PARIHAR, Neha ARYA a Amit Suresh KHAIRNAR. Association of COVID-19 with Comorbidities: An Update. ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE. WASHINGTON: AMER CHEMICAL SOC, 2023, roč. 6, č. 3, s. 334-354. ISSN 2575-9108. Dostupné z: https://dx.doi.org/10.1021/acsptsci.2c00181.

@article{2368678,
   author = {Chatterjee, Sayan and Nalla, Lakshmi Vineela and Sharma, Monika and Sharma, Nishant and Singh, Aditya A and Malim, Fehmina Mushtaque and Ghatage, Manasi and Mukarram, Mohd and Pawar, Abhijeet and Parihar, Nidhi and Arya, Neha and Khairnar, Amit Suresh},
   article_location = {WASHINGTON},
   article_number = {3},
   doi = {http://dx.doi.org/10.1021/acsptsci.2c00181},
   keywords = {COVID-19; comorbidity; diabetes; cancer; Parkinson?s disease; cardiovascular disease},
   language = {eng},
   issn = {2575-9108},
   journal = {ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE},
   title = {Association of COVID-19 with Comorbidities: An Update},
   url = {https://pubs.acs.org/doi/10.1021/acsptsci.2c00181},
   volume = {6},
   year = {2023}
}

TY  - JOUR
ID  - 2368678
AU  - Chatterjee, Sayan - Nalla, Lakshmi Vineela - Sharma, Monika - Sharma, Nishant - Singh, Aditya A - Malim, Fehmina Mushtaque - Ghatage, Manasi - Mukarram, Mohd - Pawar, Abhijeet - Parihar, Nidhi - Arya, Neha - Khairnar, Amit Suresh
PY  - 2023
TI  - Association of COVID-19 with Comorbidities: An Update
JF  - ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
VL  - 6
IS  - 3
SP  - 334-354
EP  - 334-354
PB  - AMER CHEMICAL SOC
SN  - 25759108
KW  - COVID-19
KW  - comorbidity
KW  - diabetes
KW  - cancer
KW  - Parkinson?s disease
KW  - cardiovascular disease
UR  - https://pubs.acs.org/doi/10.1021/acsptsci.2c00181
N2  - Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and jeopardized human lives. It spreads at an unprecedented rate worldwide, with serious and still-unfolding health conditions and economic ramifications. Based on the clinical investigations, the severity of COVID-19 appears to be highly variable, ranging from mild to severe infections including the death of an infected individual. To add to this, patients with comorbid conditions such as age or concomitant illnesses are significant predictors of the disease's severity and progression. SARS-CoV-2 enters inside the host cells through ACE2 (angiotensin converting enzyme2) receptor expression; therefore, comorbidities associated with higher ACE2 expression may enhance the virus entry and the severity of COVID-19 infection. It has already been recognized that age-related comorbidities such as Parkinson's disease, cancer, diabetes, and cardiovascular diseases may lead to life-threatening illnesses in COVID-19-infected patients. COVID-19 infection results in the excessive release of cytokines, called "cytokine storm", which causes the worsening of comorbid disease conditions. Different mechanisms of COVID-19 infections leading to intensive care unit (ICU) admissions or deaths have been hypothesized. This review provides insights into the relationship between various comorbidities and COVID-19 infection. We further discuss the potential pathophysiological correlation between COVID-19 disease and comorbidities with the medical interventions for comorbid patients. Toward the end, different therapeutic options have been discussed for COVID-19-infected comorbid patients.
ER  -

CHATTERJEE, Sayan, Lakshmi Vineela NALLA, Monika SHARMA, Nishant SHARMA, Aditya A SINGH, Fehmina Mushtaque MALIM, Manasi GHATAGE, Mohd MUKARRAM, Abhijeet PAWAR, Nidhi PARIHAR, Neha ARYA a Amit Suresh KHAIRNAR. Association of COVID-19 with Comorbidities: An Update. \textit{ACS PHARMACOLOGY \&{} TRANSLATIONAL SCIENCE}. WASHINGTON: AMER CHEMICAL SOC, 2023, roč.~6, č.~3, s.~334-354. ISSN~2575-9108. Dostupné z: https://dx.doi.org/10.1021/acsptsci.2c00181.

Podrobný výpis o publikaci